Qianxing Mo

11.5k total citations · 2 hit papers
138 papers, 6.2k citations indexed

About

Qianxing Mo is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Qianxing Mo has authored 138 papers receiving a total of 6.2k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Molecular Biology, 46 papers in Oncology and 22 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Qianxing Mo's work include Gene expression and cancer classification (11 papers), Acute Myeloid Leukemia Research (8 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Qianxing Mo is often cited by papers focused on Gene expression and cancer classification (11 papers), Acute Myeloid Leukemia Research (8 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Qianxing Mo collaborates with scholars based in United States, China and Japan. Qianxing Mo's co-authors include Ronglai Shen, Fengju Chen, Keith Syson Chan, Venkatraman Seshan, Marc Ladanyi, Adam B. Olshen, Sijian Wang, Jing Xiao, Nikolaus Schultz and Chris Sander and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Qianxing Mo

129 papers receiving 6.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance

2014 451 citations Qianxing Mo, Fengju Chen et al. profile →
ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors

2015 358 citations Jianfeng Shen, Yang Peng et al. Cancer Discovery profile →

Peers

Countries citing papers authored by Qianxing Mo

Since Specialization

Citations

This map shows the geographic impact of Qianxing Mo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Qianxing Mo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Qianxing Mo more than expected).

Fields of papers citing papers by Qianxing Mo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Qianxing Mo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Qianxing Mo. The network helps show where Qianxing Mo may publish in the future.

Co-authorship network of co-authors of Qianxing Mo

This figure shows the co-authorship network connecting the top 25 collaborators of Qianxing Mo. A scholar is included among the top collaborators of Qianxing Mo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Qianxing Mo. Qianxing Mo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Caspase-1–dependent pyroptosis converts αSMA ⁺ CAFs into collagen-III ^high iCAFs to fuel chemoresistant cancer stem cells 2025 ·Science Advances ·Hongbo Gao, (unknown), (unknown), (unknown), Yu‐Cheng Lee, Kazukuni Hayashi, (unknown), (unknown), (unknown), (unknown), Qianxing Mo, (unknown), Ziad M. El‐Zaatari, (unknown), Raj Satkunasivam, Fotis Nikolos, Keith Syson Chan	4
2	Phase IB study of Avelumab and whole brain radiotherapy in patients with leptomeningeal disease from solid tumors: Results and molecular analyses 2025 ·Neuro-Oncology ·Yolanda Piña, Vincent Law, Solmaz Sahebjam, Nam Tran, (unknown), (unknown), Qianxing Mo, (unknown), J. Arrington, Robert Macaulay, Sepideh Mokhtari, Brittany Evernden, Kamran Ahmed, Inna Smalley, Michael Yu, Keiran S.M. Smalley, Peter Forsyth	0
3	Investigation of Serum Albumin as a Dynamic Treatment-Specific Surrogate for Outcomes in Patients With Myelofibrosis Treated With Ruxolitinib 2024 ·JCO Precision Oncology ·Andrew Kuykendall, Somedeb Ball, Barbara Mora, Qianxing Mo, Najla Al Ali, Margherita Maffioli, Giuseppe Auteri, (unknown), Giuseppe A. Palumbo, Andrea Duminuco, (unknown), Elena Maria Elli, Francesco Passamonti, Francesca Palandri, Rami S. Komrokji	3
4	Alteration of the Tumor Microenvironment With Intratumoral Dendritic Cells Before Chemotherapy in ERBB2 Breast Cancer 2024 ·JAMA Oncology ·Hyo S. Han, Amy L. Aldrich, Saurabh Garg, R. Jared Weinfurtner, Jonathan V. Nguyen, Qianxing Mo, Junmin Whiting, Jennifer Childress, (unknown), Ricardo Costa, (unknown), Aixa Soyano, John V. Kiluk, Susan Hoover, Marie Catherine Lee, Nazanin Khakpour, (unknown), (unknown), Gary K. Koski, Brian J. Czerniecki	1
5	Safety and immunogenicity of a third dose of mRNA‐1273 vaccine among cancer patients 2023 ·Cancer Communications ·Anna R. Giuliano, Barbara J. Kuter, Shari Pilon‐Thomas, Junmin Whiting, Qianxing Mo, Brett Leav, Bradley Sirak, Christopher Cubitt, (unknown), (unknown), (unknown), Somedeb Ball, (unknown), Akriti Jain, Patrick Hwu, Jeffrey E. Lancet	6
6	Detectable Lipidomes and Metabolomes by Different Plasma Exosome Isolation Methods in Healthy Controls and Patients with Advanced Prostate and Lung Cancer 2023 ·International Journal of Molecular Sciences ·(unknown), Yijun Tian, Paul A. Stewart, Yury O. Núñez López, Brandon J. Manley, Bruna Pellini, (unknown), Jingsong Zhang, Qianxing Mo, Douglas C. Marchion, Min Liu, John M. Koomen, Erin M. Siegel, Liang Wang	8
7	Neoadjuvant therapy of HER2 directed conventional dendritic cell (DC1) intratumoral (IT) therapy plus weekly paclitaxel, trastuzumab, and pertuzumab in patients with HER-2 positive breast cancer: NATASHA trial. 2023 ·Journal of Clinical Oncology ·Hyo S. Han, Ricardo Costa, (unknown), Susan Hoover, John V. Kiluk, Marie Catherine Lee, Hatem Soliman, Hung T. Khong, Loretta Loftus, Qianxing Mo, (unknown), (unknown), (unknown), Amy L. Aldrich, (unknown), (unknown), Shannon Falcon, R. Jared Weinfurtner, (unknown), Brian J. Czerniecki	1
8	Effect of Microporous Polysaccharide Particles in Patients Undergoing Mastectomy 2022 ·Clinical Breast Cancer ·(unknown), (unknown), Junmin Whiting, (unknown), Melissa Anne Mallory, Susan Hoover, John V. Kiluk, Nazanin Khakpour, Brian J. Czerniecki, Christine Laronga, Qianxing Mo, Marie Catherine Lee	2
9	Histopathologic and transcriptomic phenotypes of a conditional RANKL transgenic mouse thymus 2022 ·Cytokine ·Maria M. Szwarc, Hai Lan, (unknown), Kimal Rajapakshe, Dimuthu Perera, Michael Ittmann, Qianxing Mo, Yong Lin, Matthew L. Bettini, Cristian Coarfa, John P. Lydon	1
10	Patient-caregiver dyads in pancreatic cancer: identification of patient and caregiver factors associated with caregiver well-being 2022 ·Journal of Behavioral Medicine ·Brent T. Xia, Amy K. Otto, Kelvin Allenson, (unknown), Wenyi Fan, Qianxing Mo, Jason W. Denbo, Mokenge P. Malafa, Jennifer B. Permuth, Dae Won Kim, Jason B. Fleming, Maija Reblin, Pamela J. Hodul	11
11	Regorafenib is effective against neuroblastoma in vitro and in vivo and inhibits the RAS/MAPK, PI3K/Akt/mTOR and Fos/Jun pathways 2020 ·British Journal of Cancer ·(unknown), (unknown), (unknown), Sean Flynn, (unknown), Jing Zhang, Karen Messer, Qianxing Mo, Shixia Huang, Jacqueline Lesperance, Peter E. Zage	33
12	Metformin and an insulin/IGF-1 receptor inhibitor are synergistic in blocking growth of triple-negative breast cancer 2020 ·Breast Cancer Research and Treatment ·Lei Xue, Fengju Chen, Yue Fei, Laura Camacho, (unknown), Guanyun Wei, Shixia Huang, Qianxing Mo, Fei Ma, Yi Li, Sao Jiralerspong	19
13	A Prospective Targeted Serum Metabolomics Study of Pancreatic Cancer in Postmenopausal Women 2019 ·Cancer Prevention Research ·Li Jiao, Suman Kumar Maity, Cristian Coarfa, Kimal Rajapakshe, Liang Chen, Feng Jin, Vasanta Putluri, Lesley F. Tinker, Qianxing Mo, Fengju Chen, Subrata Sen, (unknown), Hashem B. El‐Serag, Nagireddy Putluri	16
14	Mammary Precancerous Stem and Non-Stem Cells Evolve into Cancers of Distinct Subtypes 2018 ·Cancer Research ·Wen Bu, Zhenyu Liu, Weiyu Jiang, Chandandeep Nagi, Shixia Huang, Dean P. Edwards, Eunji Jo, Qianxing Mo, Chad J. Creighton, Susan G. Hilsenbeck, Andrew D. Leavitt, Michael T. Lewis, Stephen T.C. Wong, Yi Li	31
15	FGFR1-Activated Translation of WNT Pathway Components with Structured 5′ UTRs Is Vulnerable to Inhibition of EIF4A-Dependent Translation Initiation 2018 ·Cancer Research ·Tuan M. Nguyen, Elena B. Kabotyanski, Yongchao Dou, Lucas C. Reineke, Peng Zhang, Xiang H.-F. Zhang, Anna Malovannaya, Sung Yun Jung, Qianxing Mo, Kevin Roarty, Yiwen Chen, Bing Zhang, Joel R. Neilson, Richard E. Lloyd, Charles M. Perou, Matthew J. Ellis, Jeffrey M. Rosen	19
16	FOXO1 regulates uterine epithelial integrity and progesterone receptor expression critical for embryo implantation 2018 ·PLoS Genetics ·Yasmin M. Vasquez, Xiaoqiu Wang, Margeaux Wetendorf, Heather L. Franco, Qianxing Mo, Tianyuan Wang, Rainer B. Lanz, Steven L. Young, Bruce A. Lessey, Thomas E. Spencer, John P. Lydon, Francesco J. DeMayo	112
17	ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors breakdown → 2015 ·Cancer Discovery ·Jianfeng Shen, Yang Peng, Leizhen Wei, Wei Zhang, Lin Yang, Li Lan, Prabodh Kapoor, Zhenlin Ju, Qianxing Mo, Ie‐Ming Shih, Iván P. Uray, Xiangwei Wu, Powel H. Brown, (unknown), Gordon B. Mills, Guang Peng	358
18	A Tumorigenic Factor Interactome Connected through Tumor Suppressor MicroRNA-198 in Human Pancreatic Cancer 2013 ·Clinical Cancer Research ·Christian Marín‐Müller, Dali Li, Uddalak Bharadwaj, Min Li, Changyi Chen, Sally E. Hodges, William E. Fisher, Qianxing Mo, Mien‐Chie Hung, Qizhi Yao	73
19	Combining integrated genomics and functional genomics to dissect the biology of a cancer‐associated, aberrant transcription factor, the ASPSCR1–TFE3 fusion oncoprotein 2013 ·The Journal of Pathology ·Rachel Kobos, Makoto Nagai, Masumi Tsuda, (unknown), Tsuyoshi Saito, Marick Laé, Qianxing Mo, Adam B. Olshen, (unknown), Christina C. Leslie, Irina Ostrovnaya, Christophe Antczak, Hakim Djaballah, Marc Ladanyi	50
20	Prognostic Immune Markers in Non–Small Cell Lung Cancer 2011 ·Clinical Cancer Research ·Kei Suzuki, Stefan S. Kachala, Kyuichi Kadota, Ronglai Shen, Qianxing Mo, David G. Beer, Valerie W. Rusch, William D. Travis, Prasad S. Adusumilli	147

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact